Salima Qamruddin is a Cardiology physician affiliated with Ochsner Health System. OpenAlex indexes 48 publications with 451 citations (h-index 11); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1514 Jefferson Hwy
New Orleans, LA 701212429
Telephone
504-842-4135Registry record last updated 29 Jun 2016.
Clinical trials
- Low Ejection Fraction in Single Lead ECG- Ochsner
Sponsor: Eko Devices, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GE HEALTHCAREProgram year20256 payments$12,950openpaymentsdata.cms.gov ↗
- Edwards Lifesciences CorporationProgram year20259 payments
- E.R. Squibb & Sons, L.L.C.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
86.6%Statin21.5%Rosuvastatin Calcium47%Atorvastatin Calcium43%Pravastatin Sodium10%Part D≥73 patientsBeta blocker17.6%Metoprolol Succinate51%Carvedilol25%Metoprolol Tartrate21%Atenolol4%Part D<11 patients+ 15 more classes in this area
Blood & clotting
10.5%Factor Xa inhibitor7.9%Eliquis77%Xarelto23%Part D<11 patientsVitamin K antagonist1.3%Warfarin Sodium100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
2.9%SGLT2 inhibitor2.3%Jardiance70%Farxiga30%Part D<11 patientsPotassium supplement0.6%Potassium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Peak myocardial work assessment to detect coronary ischemia during dobutamine stress echocardiography
Frontiers in Cardiovascular Medicine
2025 - Significance of Left Atrial and Ventricular Strains in Patients With Mitral Annular Calcification
Journal of the American Society of Echocardiography
2025 - Straining to predict mortality in low flow low gradient aortic stenosis patients undergoing TAVR: can GLS and myocardial work parameters improve outcomes?
European Heart Journal - Cardiovascular Imaging
2025 - Utility of peak myocardial work index: a nonproprietary method for myocardial work evaluation in patients with cardiomyopathy
The International Journal of Cardiovascular Imaging
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Carl Lavie, MD
Ochsner Health System
Natalie Bzowej, MD
Ochsner Health System
Mark Effron, MD
Ochsner Health System
Jane Martin, MD
Ochsner Health System
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”